✨ Free AI Report
Celularity Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Celularity Inc.
Company Research

Celularity Inc.: Business Overview, Financials & Competitive Analysis

Celularity Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage regenerative medicine play with promising cell therapy platform and revenue traction, but requires careful capital deployment and clinical validation before broader institutional adoption. Celularity demonstrates strong revenue growth (138% YoY in 2024) and operational improvements, but faces structural challenges including micro-cap status (~$45M market cap), prior Nasdaq compliance issues.

What is Celularity Inc.'s industry? Celularity Inc. (celularity.com) operates in Regenerative Medicine & Cell Therapy (Biotech). AskCyborg classifies Celularity Inc. under Regenerative Medicine & Cell Therapy (Biotech) in its company registry.

Celularity Inc. is a regenerative and cellular medicines company focusing on addressing aging-related and degenerative diseases. The company develops off-the-shelf placental-derived allogeneic cell therapy product can...

4/ 10Mixed

Cyborg Score thesis

Early-stage regenerative medicine play with promising cell therapy platform and revenue traction, but requires careful capital...

Read the full analyst-debate transcript →
Industry Regenerative Medicine & Cell Therapy (Biotech)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Celularity Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Celularity Inc.

AskCyborg analysts argue the bull and bear cases for Celularity Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Celularity Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Celularity Inc. Overview

Pro stress-test →

Celularity Inc. is a regenerative and cellular medicines company focusing on addressing aging-related and degenerative diseases. The company develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease.

Strategic Profile

Pro stress-test →

The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Recently, Celularity completed a significant balance sheet restructuring by retiring $41.6 million in senior secured debt while maintaining exclusive licensing rights to its intellectual property for 5 years.

Competitive Landscape

Pro stress-test →

Celularity's therapeutic programs target aging-related diseases using mesenchymal-like adherent stromal cells, CAR T-cells, and natural killer (NK) cells. The company competes in the broader regenerative medicine and cell therapy space against established biotech firms and emerging cell therapy developers, differentiated by its exclusive access to placental-derived material sources.

Industry Context

Celularity Inc. operates in Regenerative Medicine & Cell Therapy (Biotech).

Key facts

Founded: 2018 · Headquarters: Florham Park, New Jersey, US · Revenue: $54.2M (2024) · Market cap: $45M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Celularity Inc..

  • 2024 revenue grew 138% to $54.2 million from $22.8 million in 2023
  • Successfully eliminated $41.6 million in senior secured debt through strategic IP asset sale in 2025
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Received $12.2M from sale of New Jersey net operating losses
  • December 2025Secured additional financing and announced strategic shift in capital allocation
  • +1 moreTrack every material event for Celularity Inc. as it happens. Explore monitoring →
Get alerted when Celularity Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Allogeneic Cell TherapyClinical-stage competitors developing alternative allogeneic cell therapies→CAR-T and NK Cell TherapiesEstablished players in engineered cell therapy development→Surgical BiomaterialsCompetitors in advanced wound care and surgical biomaterial markets→

Compare Celularity Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Celularity Inc. operates in Regenerative Medicine & Cell Therapy (Biotech). See how the rest of the sector scores on the Cyborg framework.

Browse Regenerative Medicine & Cell Therapy (Biotech) research →
NEW · MCP server

Ask your AI assistant about Celularity Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Celularity Inc. and its top competitor on Cyborg Score”
“What did Celularity Inc. do this quarter?”
“Is Celularity Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Celularity Inc. do?+
Celularity Inc. is a regenerative and cellular medicines company focusing on addressing aging-related and degenerative diseases. The company develops off-the-shelf placental-derived allogeneic cell therapy product can...
What is Celularity Inc.'s Cyborg Score?+
Celularity Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Celularity Inc.'s main competitors?+
Named competitors include Allogeneic Cell Therapy, CAR-T and NK Cell Therapies, Surgical Biomaterials. The full competitive landscape is in the AskCyborg report.
How can I get the full Celularity Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Celularity Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Celularity Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.